Literature DB >> 3355852

In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone.

K Y Hostetler1, J R Giordano, E J Jellison.   

Abstract

Amiodarone causes phospholipid storage in the lysosomes of various types of lung cell in animals and man. It has been proposed that this is due to its ability to inhibit lysosomal phospholipase A. To investigate this further, a crude lysosomal fraction from rat lung was prepared and phospholipase A was isolated and its positional specificity was determined. Analysis of the products formed after incubation with 2-[1-14C]oleoylphosphatidylcholine showed that only phospholipase A1 activity is present. This soluble preparation of lung lysosomal phospholipase A1 was used to study inhibition by amiodarone and desethylamiodarone, in vitro. Both were extremely potent inhibitors of the lung acid phospholipase A1. To evaluate the levels of amiodarone in lung lysosomes, rats were treated with the agent for 3 days and the combined mitochondrial/lysosomal fraction of lung tissue was prepared by differential centrifugation. This fraction had been shown previously to be highly enriched in amiodarone. Purified mitochondria and lysosomes were isolated from the combined mitochondrial/lysosomal fraction with Percoll gradients and analyzed for their drug content by HPLC. Amiodarone and desethylamiodarone were present in roughly equal amounts, relative to protein, in mitochondria and lysosomes, respectively. Amiodarone appears to differ from other cationic amphiphilic drugs which cause lipidosis because the latter are more highly lysosomotropic. Although amiodarone does not appear to be highly lysosomotropic in lung, it causes lysosomal phospholipid storage because of its ability to concentrate in lung and because it inhibits lysosomal phospholipase A to a much greater extent than other cationic amphiphiles such as diethylaminoethoxyhexestrol, chloroquine and chlorphentermine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355852     DOI: 10.1016/0005-2760(88)90205-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells.

Authors:  I Scuntaro; U Kientsch; U N Wiesmann; U E Honegger
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Amiodarone-induced pulmonary toxicity in the rat.

Authors:  B D Wilson; A J Jaworski; M E Donner; M L Lippmann
Journal:  Lung       Date:  1989       Impact factor: 2.584

3.  Amiodarone and bepridil inhibit anthrax toxin entry into host cells.

Authors:  Ana M Sanchez; Diane Thomas; Eugene J Gillespie; Robert Damoiseaux; Joseph Rogers; Jonathan P Saxe; Jing Huang; Marianne Manchester; Kenneth A Bradley
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

4.  Role of phospholipases in myocardial ischemia: effect of cardioprotective agents on the phospholipases A of heart cytosol and sarcoplasmic reticulum in vitro.

Authors:  K Y Hostetler; E J Jellison
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

5.  Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

Authors:  K M Waldhauser; K Brecht; S Hebeisen; H R Ha; D Konrad; D Bur; S Krähenbühl
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

6.  Amiodarone--induced changes in surfactant phospholipids of rat lung.

Authors:  B Padmavathy; H Devaraj; N Devaraj
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-04       Impact factor: 3.000

7.  Amiodarone causes decreased cell-mediated immune responses and inhibits the phospholipase C signaling pathway.

Authors:  B D Wilson; C E Clarkson; M L Lippmann
Journal:  Lung       Date:  1993       Impact factor: 2.584

8.  Acute silica toxicity: attenuation by amiodarone-induced pulmonary phospholipidosis.

Authors:  J M Antonini; C M McCloud; M J Reasor
Journal:  Environ Health Perspect       Date:  1994-04       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.